BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

FDA Gives Permission To Use Very Sensitive Molecular Evidence Of Cancer In BiovaxID Pivotal Phase 3: Company Intends To Use Blood Test To File Application For Accelerated Approval


5/16/2006 12:53:14 PM

WORCESTER, Mass.--(BUSINESS WIRE)--May 16, 2006--Biovest International, Inc. (OTCBB: BVTI - News) has been notified by the United States Food and Drug Administration (FDA) that its proposal to utilize molecular remissions data as a new secondary endpoint in its ongoing clinical trial is acceptable to the agency. Biovest is conducting a pivotal Phase 3 trial evaluating BiovaxID(TM), the Company's personalized, targeted anti-cancer immunotherapy for treatment of follicular non-Hodgkin's lymphoma at over 20 major medical centers throughout the U.S. Biovest previously reported positive Phase 2 results for BiovaxID - more than 9 years after treatment 95% of BiovaxID treated patients are still alive. Approximately 70 % of evaluable patients showed no evidence of tumor cells when measured using highly precise molecular remissions data.

Read at press release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->